Preview

Вопросы гематологии/онкологии и иммунопатологии в педиатрии

Расширенный поиск

L-аспарагиназа: новые подходы к улучшению фармакологических свойств

https://doi.org/10.24287/1726-1708-2018-17-4-82-99

Полный текст:

Аннотация

Обзор посвящен противоопухолевому препарату L-аспарагиназе, его свойствам, механизму
действия, а также новым лекарственным формам, обладающим улучшенными показателями эффективности, безопасности и фармакокинетики. Особое внимание уделено L-аспарагиназе, включенной в эритроциты.

Об авторах

Д. В. Борсакова
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России; ФГБУН «Центр теоретических проблем физико-химической фармакологии» РАН.
Россия

мл. научный сотрудник лаборатории биофизики.

 117997, Москва, ГСП-7, ул. Саморы Машела, 1. 



Е. И. Синауридзе
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России; ФГБУН «Центр теоретических проблем физико-химической фармакологии» РАН.
Россия


Список литературы

1. Verma N., Kumar К., Kaur G., Anand S. L-asparaginase: a promis¬ing chemotherapeutic agent. Crit Rev Biotechnol 2007; 27 (1): 45-62.

2. Piatkowska-Jakubas B., Krawczyk- Kulis M., Giebel S., Adamczyk-Cioch M., Czyz A., Lech Maranda E., et at. Polish Adult Leukemia Group. Use of L-asparaginase in acute lympho¬blastic leukemia: recommendations of the Polish Adult Leukemia Group. Pol Arch Med Wewn 2008; 118 (11): 664-9.

3. Sanson E., Jaskolski M. Structure, dynamics and electrostatics of the L-asparaginase catalytic centre: Implications for reaction mechanism. Department of Crystallography, Birkbeck College, London and Venus Internet Ltd., London, UK. Available at: http://www, man.poznan.pl/CBB/POSTERl/poster. html#xtal (accessed April 20, 2018).

4. Kidd J.G. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Courses of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum or rabbit serum. J Exp Med 1953; 95 (6): 565-82.

5. Old L.J., Boyse E.A., Campbell H.A., Daria G.M. Leukemia-inhibiting proper-ties and L-asparaginase activity of sera from certain South American rodents. Nature 1963; May 25; 198 (4882): 801.

6. Wriston J.C., Yellin T.O. L-asparaginase: a review. Adv Enzymol Relat Areas Mol Biol 1973; 39: 185-248.

7. Oettgen H.F., Old L.J., Boyse E.A., Campbell H.A., Philips F.S., Clarkson B.D., et al. Inhibition of leukemias in man by L-asparaginase. Cancer Res 1967; 27(12): 2619-31.

8. Hill J.M., Roberts J., Loeb E., Khan A., MacLellan A., Hill R.W. L-asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia. JAMA 1967; 202 (9): 882-8.

9. Del Casale T., Sollitti P., Chesney R.H. Cytoplasmic L-asparaginase: isolation of a defective strain and mapping of ansA. J Bacteriol 1983; 154 (1): 513-5.

10. Jennings M.P., Beacham I.R. Analysis of the Escherichia coli gene encoding L-asparaginase II, ansB, and its regulation by cyclic AMP receptor and FNR proteins. J Bacteriol 1990; 172 (3): 1491-8.

11. Sanches M., Krauchenco S., Polikar- pov I. Structure, substrate complexation and reaction mechanism of bacterial asparaginases. Curr Chem Biol 2007; 1 (1): 75-86.

12. Whitecar J.P.Jr., Bodey G.P., Har¬ris J.E., Freireich E.J. L-Asparaginase. N Engl J Med 1970; 282 (13): 732-4. DOI: 10.1056/NEJM197003262821307

13. Ho P.P.K., Milikin E.B., Bobbitt J.L., Grinnan E.L., Burck P.J., Frank B.H., et al. Crystalline L-asparaginase from Escherichia coli B: I. Purification and chemical characterization. J Biol Chem 1970; 245 (14): 3708-15.

14. Kozak M., Jurga S. A comparison between the crystal and solution structures of Escherichia coli asparaginase II. Acta Biochim Pol 2002; 49 (2): 509-13.

15. Swain A.L., Jaskôlski M., Housset D., Rao J.K., Wlodawer A. Crystal structure of Escherichia coli L-asparaginase, an enzyme used in cancer therapy. Proc Natl Acad Sci USA 1993; 90 (4): 1474-8.

16. Lubkowski J., Dauter M., Aghaiy- pour K., Wlodawer A., Dauter Z. Atomic resolution structure of Erwinia chrysanthemi L-asparaginase. Acta Crystallogr D Biol Crystallogr 2003; 59 (Pt 1): 84-92.

17. Palm G.J., Lubkowski J., Derst C., Shleper S., Rohm K.H., Wlodawer A. A covalently bound catalytic inter¬mediate in Escherichia coli aspara¬ginase: crystal structure of a Thr-89-Val mutant. FEBS Lett 1996; 390 (2): 211-6.

18. Yun M.K., Nourse A., White S.W., Rock C.O., Heath R.J. Crystal structure and allosteric regulation of the cytoplasmic Escherichia coli L-asparaginase I. J Mol Biol 2007; 369 (3): 794-811.

19. Илларионова H., Петров Л., Оленнико- ва Л.Б РОЩИН С., Пасечник В. Изучение вторичной структуры L-аспарагиназы В широкой области pH величин. Молекулярная БИОЛОГИЯ 1980; 14 (4): 951-5.

20. Мардашев С.Р., Николаев А., КОЗ¬ЛОВ Е.А., Петрий О.П. Очистка микробных аспарагиназ с помощью аффинной хроматографии. БИОХИМИЯ 1975; 40 (1): 78-82.

21. Agrawal V., Woo J.H., Borthakur G., Kantarjian H., Frankel A.E. Red blood cell-encapsulated L-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia. Protein Pept Lett 2013; 20 (4): 392-402. Available at: http://www.eurekaselect.com/openurl/ content.php?genre=article&issn=0929- 8665&volume=20&issue=4&spage=392 (accessed April 20, 2018).

22. Ueno T., Ohtawa K., Mitsui K., Kode- ra Y., Hiroto M., Matsushima A., et al. Cell cycle arrest and apoptosis of leukemia cells induced by L-asparaginase. Leukemia 1997; 11 (11): 1858-61.

23. Covini D., Tardito S., Bussolati O., Chiarelli L., Pasquetto M., Digilio R., et al. Expanding targets for a metabolic therapy of cancer: L-asparaginase. Recent Pat Anticancer Drug Discov 2012; 7 (1): 4-13.

24. Cooney D.A., Capizzi R.L., Handschu-macher R.E. Evaluation of L-asparagine metabolism in animals and man. Cancer Res 1970; 30 (4): 929-35.

25. Divino Filho J.C., Barany P., Stehle P., Furst P., Bergstrom J. Free amino acid levels simultaneously collected in plasma, muscle and erythrocytes of uraemic patients. Nephrol Dial Transplant 1997; 12 (11): 2339-48. DOI: https://doi.org/10.1093/ndt/12.11. 2339

26. Conter V., Bartram C.R., Valsecchi M.G., Schrauder A., Panzer-Grumayer R., Moricke A., et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115 (16): 3206-14.

27. Derst C., Henseling J., Rohm K.H. Engineering the substrate specificity of Escherichia coli asparaginase. II. Selective reduction of glutaminase activity by amino acid replacements at position 248. Protein Sci 2000; 9 (10): 2009-17.

28. Zoncu R., Sabatini D.M., Efeyan A. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12 (1): 21-35. DOI: 10.1038/nrm3025

29. Nicklin P., Bergman P., Zhang B., Triantafellow E., Wang H., Nyfeler B., et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 2009; 136 (3): 521-34.

30. Clavell L.A., Gelber R.D., Cohen H.J., Hitchcock-Bryan S., Cassady J.R., Tarbell N.J., et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. New Engl J Med 1986; 315 (11): 657-63.

31. Nesbit M., Chard R., Evans A., Karon M., Hammond G. Evaluation of intramuscular verses intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol 1979; 1 (1): 9-13.

32. Müller H.J., Boos J. Use of L-aspar- aginase in childhood ALL. Crit Rev Oncol Hematol 1998; 28 (2): 97-113.

33. Desai S., Barr R., Andrew M., deVeber L., Pai M. Management of Ontario children with acute lymphoblastic leukemia by the Dana-Farber Cancer Institute protocols. Can Med Assoc J 1989; 141 (7): 693-7.

34. Nachman J., Sather H.N., Gaynon P.S., Lukens J.N., Wolff L., Trigg M.E. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. J Clin Oncol 1997; 15 (6): 2222-30.

35. Silverman L.B., Gelber R.D., Dalton V.K., Asselin B.L., Barr R.D., Clavell L.A., et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97 (5): 1211-8.

36. Richards N.G., Kilberg M.S. Asparagine synthetase chemotherapy. Annu Rev Biochem 2006; 75: 629-54.

37. Clarkson B., Krakoff I., Burchenal J., Karnofsky D., Golbey R., Dowling M., et al. Clinical results of treatment with E. coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors. Cancer 1970; 25 (2): 279-305.

38. Crowther D. L-Asparaginase and human maligmant disease. Nature 1971; 229 (5281): 168-71.

39. Capizzi R.L., Bertino J.R., Skeel R.T., Creasey W.A., Zanes R., Olayon C., et al. L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med 1971; 74 (6): 893-901.

40. Jaccard A., Gachard N., Marin B., Ro- gez S., Audrain M., Suarez F., et al. GELA and GOELAMS Intergroup. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 2011; 117 (6): 1834-9.

41. Matsumoto Y., Nomura K., Kanda- Akano Y., Fujita Y., Nakao M., Ueda K., et al. Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T-cell lymphoma. Leuk Lymphoma 2003; 44 (5): 879-82.

42. Koishi T., Minowada J., Henderson E.S., Ohnuma T. Distinctive sensitivity of some T-leukemia cell lines to L-asparaginase. Gan 1984; 75 (3): 275-83.

43. Moola Z.B., Scawen M.D., Atkinson T., Nicholls D.J. Erwinia chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes. Biochem J 1994; 302 (Pt 3): 921-7.

44. Keating M.J., Holmes R., Lerner S., Ho D.H. L-asparaginase and PEG asparaginase - past, present, and future. Leuk Lymphoma 1993; 10 (Suppl. 1): 153-7.

45. Lorenzi P.L., Reinhold W.C., Rudelius M., Gunsior M., Shankavaram U., Bussey K.J., et al. Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther 2006; 5 (11): 2613-23.

46. Tardito S., Uggeri J., Bozzetti C., Bian- chi M.G., Rotoli B.M., Franchi-Gaz- zola R., et al. The inhibition of gluta¬mine synthetase sensitizes human sarcoma cells to L-asparaginase. Can¬cer Chemother Pharmacol 2007; 60 (5): 751-8.

47. Cappelletti D., Chiarelli L.R., Pasquet- to M.V., Stivala S., Valentini G., Scotti C. Helicobacter pylori L-asparaginase: A promising chemotherapeutic agent. Biochem Biophys Res Commun 2008; 377 (4): 1222-6.

48. Pieters R., Hunger S.P., Boos J., Riz- zari C., Silverman L., Baruchel A., et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 2011; 117 (2): 238-49.

49. Van Den Berg H. Asparaginase revisi-ted. Leuk Lymphoma 2011; 52 (2): 168-78.

50. Müller H., Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 1998; 28 (2): 97-113.

51. Capizzi R.L., Cheng Y.-C. Therapy of neoplasia with asparaginase. In: Enzymes as Drugs (Holcenberg J.S., Roberts I. eds.). N.Y., John Wiley and Sons, 1981; pp. 1-24.

52. Hersh E.M. Immunosuppression by L-asparaginase and related enzymes. Transplantation 1971; 12 (5): 368-76.

53. Kafkewitz D., Bendich A. Enzyme- induced asparagine and glutamine depletion and immune system function. Am J Clin Nutr 1983; 37 (6): 1025-30.

54. Kelo E., Noroncoski T., Stoin- eva I.B., Petkov D.D., Mononen I. P-Aspartylpeptides as substrates of L-asparaginases from Escherichia coli and Erwinia chrysanthemi. FEBS Lett 2002; 528 (1-3): 130-2.

55. Akbayram S., Dogan M., Akgün C.,Caksen H., Oner A.F. A desensitization protocol in children with L-asparaginase hypersensitivity. J Pediatr Hematol Oncol 2010; 32 (5): e187-91.DOI: 10.1097/MPH.0b013e3181e003c7

56. Ohnuma T., Holland J.F., Freeman A., Sinks L.F. Biochemical and pharma-cological studies with asparaginase in man. Cancer Res 1970; 30 (9): 2297-305.

57. Offman M.N., Krol M., Patel N., Krish- nan S., Liu J., Saha V., et al. Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicity. Blood 2011; 117 (5): 1614-21.

58. Newsted W.J., Ramjeesingh M., Zywu- Iko M., Rothstein S.J., Shami E.Y. Engineering resistance to trypsin inactivation into L-asparaginase through the production of a chimeric protein between the enzyme and a protective single-chain antibody. Enzyme Microb Technol 1995; 17 (8): 757-64.

59. Lorenzi P.L., Weinstein J.N., Cap- len N.J. Materials and methods direc¬ted to asparagine synthetase and asparaginase therapies. United States Patent NO US7985548 B2, JUI 26, 2011.

60. Ponomarenko J., Bui H.H., Li W., Fusseder N., Bourne P.E., Sette A., et at. ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics 2008 Dec 2; 9:514. DOI: 10.1186/1471-2105-9-514

61. Ansari H.R., Raghava G.P. Identification of conformational B-cell Epitopes in an antigen from its primary sequence. Immunome Res 2010 Oct 20; 6: 6. DOI: 10.1186/1745-7580-6-6

62. Werner A., Rohm K.H., Muller H.J. Mapping of B-cell epitopes in E. coli asparaginase II, an enzyme used in leukemia treatment. Biol Chem 2005; 386 (6): 535-40. DOI: https://doi.org/ 10.1515/BC.2005.063

63. Distasio J.A., Niederman R.A., Kafke- witz D., Googman D. Purification and characterization of L-asparaginase with anti-lymphoma activity from Vibrio succinogenes. J Bol Chem 1976; 251 (22): 6929-33.

64. Roberts J., MacAllister T.W., Sethura- man N., Abbie G. Freeman A.G. Genetically engineered glutaminase and its use in antiviral and anticancer therapy. United States Patent NO US6312939 B1, Nov 6, 2001.

65. Roberts J. Purification and properties of a highly potent antitumor glutaminase- asparaginase from Pseudomonas 7A. J Biol Chem 1976; 251 (7): 2119-23.

66. Roberts J., Schmid F.A., Rosenfeld H.J. Biologic and antineoplastic effects of enzyme-mediated in vivo depletion of L-glutamine, L-tryptophan, and L-histidine. Cancer Treat Rep 1979; 63 (6): 1045-54.

67. Noronkoski T., Stoineva I.B., Pet- kov D.D., Mononen I. Recombinant hum¬an glycosylasparaginase catalyzes hydrolysis of L-asparagine. FEBS Lett 1997; 412 (1): 149-52.

68. Kelo E., Noronkoski T., Mononen I. Depletion of L-asparagine supply and apoptosis of leukemia cells induced by human glycosylasparaginase. Leukemia 2009; 23 (6): 1167-71.

69. Kim K., Jeong J.H., Lim D., Hong Y., Lim H.J., Kim G.J., et al. L-Asparaginase delivered by Salmonella typhimurium suppresses solid tumors. Mol Ther Oncolytics 2015 Jun 10; 2: 15007. Available at: http://dx.doi.org/10.1038/ mto.2015.7 (accessed April 20, 2018).

70. Kamisaki Y., Wada H., Yagu- ra T., Matsushima A., Inada Y. Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycol. J Pharmacol Exp Ther 1981; 216 (2): 410-4.

71. Yoshimoto T., Nishimura H., Saito Y., Sakurai K., Kamisaki Y., Wada H., et al. Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia. Jpn J Cancer Res 1986; 77 (12): 1264-70.

72. FU C.H., Sakamoto K.M. PEG-aspara-ginase. Expert Opin Pharmacother 2007; 8 (12): 1977-84.

73. Asselin B.L., Whitin J.C., Coppo¬la D.J., Rupp I.P., Sallan S.E., Cohen H.J. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993; 11 (9): 1780-6.

74. Graham M.L. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev 2003; 55 (10): 1293-302.

75. Rizzari C., Citterio M., Zucchetti M., Conter V., Chiesa R., Colombini A., et al. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Heamatologica 2006; 91 (1): 24-31.

76. Armstrong J.K., Hempel G., Koling S., Chan L.S., Fisher T., Meiselman H.J., et al. Antibody against poly (ethylene glycol) adversely affects PEG-asparagin¬ase therapy in acute lymphoblastic leukemia patients. Cancer 2007; 110 (1): 103-11.

77. Abribat T. Pegylated L-asparaginase. WO Application NO WO2011003886 A1 (13.01.2011). Available at: https://patents.google.com/patent/ WO2011003886A1/en (accessed April 20, 2018).

78. Allas S., Sahakian P., Fichtner I., Abribat T. Pharmacokinetics and pharmacodynamics in mice of a pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase. 51st ASH Annual Meeting Abstracts. Blood 2009; 114 (22): abstract [2033].

79. Martins M.B., Jorge J.C., Cruz M.E. Acylation of L-asparaginase with total retention of enzymatic activity. Biochimie 1990; 72 (9): 671-5.

80. Poznansky M.J., Shandling M., Sal- kie M.A., Elliott J.F., Lau E. Advantages in the use of L-asparaginase-albumin polymer as an antitumor agent. Cancer Res 1982; 42 (3): 1020-5.

81. Zhang Y.Q., Zhou W.L., Shen W.D., Chen Y.H., Zha X.M., Shirai K., et al. Synthesis, characterization and immunogenicity of silk fibroin-L- asparaginase bioconjugates. J Biotech- nol 2005; 120 (3): 315-26.

82. Karsakevich A.S., Vina I.A., Liduma G.Y.A. Immobilization of the enzyme E. coli L-asparaginase on a water- soluble copolymer of vinylpyrrolidone and acrolein. Chem Nat Compd 1988; 24(4): 477-80. DOI: https://doi.org/10.1007/BF00598537

83. Карсакевич A.C., Кинстлер О.Б.,Дауварте А.Х. Биологические свойства высокомолекулярных производных L-аспарагиназы, полученных после иммобилизации фермента на водно-растворимой карбоксиметил- целлюлозе. Ворп Мед Хим 1988; 34 (4): 107-10.

84. Qian G., Zhou J., Ma J., Wang D., He B. The chemical modification of E. coli L-asparaginase by N,O-carboxymethyl chitosan. Artif Cells Blood Substit Immobil Biotechnol 1996; 24 (6): 567-77.

85. Карсакевич Ф.С., Дауварте A.X., Звиргжда И.К., Лебедева Л.В., Вина И.А. Эффективные комплексы антилейке- мического фермента L-аспарагиназы С декстрансульфатом. Ворп Мед Хим 1986; 32(4): 47-51.

86. Vina I., Karsakevich A., Bekers, M. Stabilization of anti-leukemic enzyme L-asparaginase by immobilization on polysaccharide levan. J Mol Catal B: Enzym 2001; 11 (4-6): 551-8.

87. Edman P., Nylen U., Sjoholm I. Use of immobilized L-asparaginase in acrylic microparticles in an extracorporeal hollow-fiber dialyzer. J Pharmacol Exp Ther 1983; 225 (1): 164-7.

88. Fernandes A.I., Gregoriadis G. Polysialyated asparaginase: preparation, activity and pharmacokinetics. Biochim Biophys Acta 1997; 1341 (1): 26-34.

89. Jean-François J., Fortier G. Immobi-lization of L-asparaginase into a bio-compatible poly(ethylene glycol)- albumin hydrogel: I: Preparation and in vitro characterization. Biotechnol Appl Biochem 1996; 23 (Pt 3): 221-6.

90. Jean-François J., D'Urso E.M., Forti¬er G. Immobilization of L-asparaginase into a biocompatible poly(ethylene glycol)-albumin hydrogel: evaluation of performance in vivo. Biotechnol Appl Biochem 1997; 26 (Pt 3): 203-12.

91. Gaspar M.M., Perez-Soler R., Cruz M.E. Biological characterization of L-asparaginase liposomal formulations. Cancer Chemother Pharmacol 1996; 38 (4): 373-7.

92. Gaspar M.M., Blanco D., Cruz M.E., Alonso M.J. Formulation of L-aspara- ginase-loaded poly(lactide-coglyco- lyde)nanoparticles: influence of polymer properties on enzyme loading, activity and in vitro release. J Control Release 1998; 52 (1-2): 53-62.

93. Wolf M., Wirth M., Pittner F., Gabor F. Stabilisation and determination of the biological activity of L-asparaginase in poly(D, L-lactide-co-glycolide) nano-spheres. Int J Pharm 2003; 256 (1-2): 141-52.

94. Baran E.T., Ozer N., Hasirci V. In vivo half life of nanoencapsulated L-asparaginase. J Mater Sci Mater Med 2002; 13 (12): 1113-21.

95. Wang R., Xia B., Li B.J., Peng S.L., Ding L.S., Zhang S. Semi-permeable nanocapsules of konjac glucomannan- chitosan for enzyme immobilization. Int J Pharm 2008; 364 (1) 6: 102-7.

96. Teodor E., Litescu S.C., Lazar V., Somo- ghi R. Hydrogel-magnetic nanoparticles with immobilized L-asparaginase for biomedical applications. J Mater Sci Mater Med 2009; 20 (6): 1307-14.

97. Wan S., He D., Yuan Y., Yan Z.,Zhang X., Zhang J. Chitosan-modified lipid nanovesicles for efficient systemic delivery of L-asparaginase. Colloids Surf В Biointerfaces 2016 Jul 1, 143: 278-84. DOI: 10.1016/j.colsurfb.2016.03.046

98. Атауллаханов Ф.И., ВИТВИЦКИЙ B.M., ЖЭ6ОТИНСКИЙ A.M., Пичугин А.В. Проницаемость эритроцитов человека ДЛЯ аспарагина. БИОХИМИЯ 1985; 50 (10): 1733-7.

99. Updike S.J., Wakamiya R.T. Infusion of red blood cell-loaded asparaginase in monkey. J Lab Clin Med 1983; 101 (5): 679-91.

100. Naqi A., DeLoach J.R., Andrews K., Satterfield W., Keeling M. Determination of parameters for enzyme therapy using L-asparaginase entrapped in canine erythrocytes. Biotechnol Appl Biochem 1988; 10 (4): 365-72.

101. Alpar H.O., Lewis D.A. Therapeutic efficacy of asparaginase encapsulated in intact erythrocytes. Biochem Pharmacol 1985; 34 (2): 257-61.

102. Kravtzoff R., Ropars C., Laguerre M., Muh J.P., Chassaigne M. Erythrocytes as carriers for L-asparaginase. Methodological and mouse in vivo studies. J Pharm Pharmacol 1990; 42 (7): 473-6.

103. Sinauridze E.I., Vitvitsky V.M., Pichu- gin A.V., Zhabotinsky A.M., Ataullakha- nov F.I. A new chemotherapeutic agent: L-asparaginase entrapped in red blood cells. Adv Exp Med Biol 1992; 326: 203-6.

104. Kwon Y.M., Chung H.S., Moon C., Yockman J., Park Y.J., Gitlin S.D., et al. L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL). J Control Release 2009; 139 (3): 182-9. DOI: 10.1016/j.jconrel.2009.06.027

105. Lorentz K.M., Kontos S., Diaceri G.,Henry H., Hubbell J.A. Engineered binding to erythrocytes induces immunological tolerance to E coli asparaginase. Sci Adv 2015 Jul 17; 1 (6): e1500112. DOI: 10.1126/sciadv.1500112

106. Синауридзе Е.И. Способ получения эритроцитов, заполненных лекар-ственным веществом. Авторское свидетельство СССР, № 1469609, 01.12.1988.

107. Аграненко В.А., Атауллаханов Ф.И., ВИТВИЦКИЙ B.M., КИЯТКИН А.Б., Жаботинский A.M., Маркова Н.А. И др. Способ консервирования фармакоци- ТОВ С включенной L-аспарагиназой. Авторское свидетельство СССР № 1777887, 01.08.1992.

108. Kravtzoff R., Desbois I., Lamag- nere J.P., Muh J.P., Valat C., Cha- ssaigne M., et al. Improved pharma¬codynamics of L-asparaginase-loaded in human red blood cells. Eur J Clin Pharm 1996; 49 (6): 465-70.

109. Kravtzoff R., Colombat P., Desbois I., Linassier C., Muh J.P., Philip T., et al. Tolerance evaluation of L-asparaginase loaded in red blood cells. Eur J Clin Pharmacol 1996; 51 (3-4): 221-5.

110. Domenech C., Thomas X., Chabaud S., Baruchel A., Gueyffier F., Mazingue F., et al. L-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br J Haematol 2011; 153 (1): 58-65.

111. Hunault-Berger M., Leguay T., Hugu- et F., Lepretre S., Deconinck E., Ojeda- Uribe M., et al. Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL).. A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study. Am J Hematol 2015; 90 (9): 811-8.


Для цитирования:


Борсакова Д.В., Синауридзе Е.И. L-аспарагиназа: новые подходы к улучшению фармакологических свойств. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2018;17(4):82-99. https://doi.org/10.24287/1726-1708-2018-17-4-82-99

For citation:


Borsakova D.V., Sinauridze E.I. L-asparaginase: new approaches to improve pharmacological characteristics. Pediatric Hematology/Oncology and Immunopathology. 2018;17(4):82-99. (In Russ.) https://doi.org/10.24287/1726-1708-2018-17-4-82-99

Просмотров: 166


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-1708 (Print)
ISSN 2414-9314 (Online)